Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Praxbind | Idarucizumab (Drug Plan Submission) | Reversal of dabigatran anticoagulant effects | Withdrawn | |||
| Venclexta | Venetoclax | Withdrawn | ||||
| Cyramza | Ramucirumab | Cancelled | ||||
| Adcetris | Brentuximab vedotin | Withdrawn | ||||
| Dificid | fidaxomicin | Clostridium difficile infection | Active | |||
| Talzenna | talazoparib | Metastatic castration-resistant prostate cancer (mCRPC) | Suspended | |||
| Ultomiris | ravulizumab | Generalized Myasthenia Gravis | Pending | |||
| Adcetris | brentuximab vedotin | Hodgkin lymphoma | Withdrawn | |||
| Winlevi | clascoterone | Acne vulgaris | Withdrawn | |||
| Leqvio | inclisiran | Primary hypercholesterolemia | Active |
Last Updated : May 9, 2024